Crescent Biopharma (CBIO) Shares Outstanding (Diluted Average) (2013 - 2024)

Crescent Biopharma (CBIO) has 10 years of Shares Outstanding (Diluted Average) data on file, last reported at $64.5 million in Q4 2024.

• Quarterly Shares Outstanding (Diluted Average) rose 1.79% year-over-year to $64.5 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $64.5 million (up 1.79% YoY) and the FY2024 annual result came in at $64.5 million, up 1.79% from the prior year.
• Shares Outstanding (Diluted Average) steadied at $64.5 million in Q4 2024 per CBIO's latest filing, from $64.5 million in the prior quarter.
• Across five years, Shares Outstanding (Diluted Average) topped out at $64.5 million in Q1 2024 and bottomed at $45.7 million in Q4 2020.
• The 5-year median for Shares Outstanding (Diluted Average) is $52.5 million (2022), against an average of $57.1 million.
• The widest annual swing landed in 2023, when Shares Outstanding (Diluted Average) grew 23.17%; it then gained 0.1% in 2024.
• Tracing CBIO's Shares Outstanding (Diluted Average) over 5 years: stood at $45.7 million in 2020, then gained by 12.54% to $51.5 million in 2021, then rose by 2.1% to $52.5 million in 2022, then gained by 20.58% to $63.3 million in 2023, then gained by 1.79% to $64.5 million in 2024.
• Per Business Quant, the three latest CBIO Shares Outstanding (Diluted Average) figures stand at $64.5 million (Q4 2024), $64.5 million (Q3 2024), and $64.5 million (Q2 2024).

Peer Comparison